Last reviewed · How we verify
MIS — Competitive Intelligence Brief
marketed
Plasma-derived immunoglobulin preparation or blood product
Hematology / Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
MIS (MIS) — Blood Transfusion Centre of Slovenia. MIS is a blood product derived from donated human blood that restores or replaces deficient blood components.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MIS TARGET | MIS | Blood Transfusion Centre of Slovenia | marketed | Plasma-derived immunoglobulin preparation or blood product |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Plasma-derived immunoglobulin preparation or blood product class)
- Blood Transfusion Centre of Slovenia · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MIS CI watch — RSS
- MIS CI watch — Atom
- MIS CI watch — JSON
- MIS alone — RSS
- Whole Plasma-derived immunoglobulin preparation or blood product class — RSS
Cite this brief
Drug Landscape (2026). MIS — Competitive Intelligence Brief. https://druglandscape.com/ci/mis. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab